1.30
-2.26%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BioVie
From its filings with the US Securities and Exchange Commission
BioVie is based in Carson City, Nevada and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker BIVI. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 30 June 2026, it reported a net loss of $22.1m. At that date it held total assets of $14.3m and shareholders' equity of $10.3m.
PD, and approximately 20 million adults in the US suffering from Long COVID, with millions more affected worldwide.
COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period, generally three months or more.
The U.S. patents and pending patent applications and their projected expiration dates are provided below.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Quoted from its 10-K, filed 13 Aug 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jan 2014
- Employees
- 18
- Website
- bioviepharma.com ↗
- Head office
- 680 W NYE LANE, CARSON CITY, NV, 89703
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. James LangIndependent Chairman of the Board$170,954
- Mr. Viet Cuong DoPresident, Chief Executive Officer, Director, since 2016$860,149
- Ms. Joanne KimChief Financial Officer, Corporate Secretary$420,621
- Dr. Joseph PalumboChief Medical Officer$666,051
- Dr. Amy ChappellIndependent Director
- Mr. Kameel FaragIndependent Director
- Mr. Sigmund RogichIndependent Director$150,146
- Mr. Michael ShermanIndependent Director$159,305
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 23
- Social
- 12
- Governance
- 40
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BioVie's drug candidate NE3107 targets neuroinflammation and insulin resistance in neurodegenerative diseases.
- BIV201 is an orphan drug for refractory ascites due to liver cirrhosis with continuous infusion terlipressin.
- The company focuses on biopharmaceutical development with 18 employees in Carson City, Nevada.
Weaknesses
- BioVie has only 18 employees and limited resources for drug development.
- The company's IPO in 2014 has not led to significant market expansion or revenue growth.
- NE3107 and BIV201 are still in development stages without approved market products.
Opportunities
- The orphan drug BIV201 addresses unmet needs in liver cirrhosis treatment for refractory ascites.
- NE3107 could target neurodegenerative diseases with growing prevalence globally.
- BioVie may attract partnerships for drug development in the Health Care sector.
Threats
- BioVie faces competition from larger biopharmaceutical companies in drug development.
- Regulatory hurdles could delay approval of NE3107 and BIV201 in the US market.
- The company's small size limits its ability to withstand financial pressures in the Health Care industry.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.